NEUROBIOLOGY OF ACUPUNCTUE ANALGESIA

Information

  • Research Project
  • 2390983
  • ApplicationId
    2390983
  • Core Project Number
    R01DA003983
  • Full Project Number
    2R01DA003983-10
  • Serial Number
    3983
  • FOA Number
  • Sub Project Id
  • Project Start Date
    9/1/1987 - 37 years ago
  • Project End Date
    6/30/2000 - 24 years ago
  • Program Officer Name
    THOMAS, DAVID DALE
  • Budget Start Date
    9/15/1997 - 27 years ago
  • Budget End Date
    6/30/1998 - 26 years ago
  • Fiscal Year
    1997
  • Support Year
    10
  • Suffix
  • Award Notice Date
    9/8/1997 - 27 years ago

NEUROBIOLOGY OF ACUPUNCTUE ANALGESIA

DESCRIPTION: (Applicant's Abstract) In the preceding grant periods (87-90, 90-94, 94-97) the mechanisms of pain relief by electro-acupuncture (EA) were extensively studied in animal models. The same approaches with newly developed technologies will be used in the upcoming studies. The first aim is to construct new model of chronic pain in the rat which would be closer to clinical arthritis and causes less suffering for the animal, so that it can be used for the searching of optimal parameters of EA. In addition, since multiple EA sessions are usually needed, it is important to know the optimal time intervals one should take between two EA treatments. The second aim is to study the factors affecting the efficacy of EA-induced analgesia. It has been shown that the effect of EA is determined by a balance between opioid- and the anti-opioid peptides (notably the small peptide CCK-8) in the central nervous system (CNS). It is important to learn if there are other and-opioid peptides existing in the CNS. In 1995, a novel peptide entitled orphan in FQ (OFQ) was characterized from the rat brain. While there is controversy as to whether this peptide works pro or against traditional opioids, findings obtained in this lab, which was reported in 1996 INRC pointed clearly that this is a new antiopioid peptide, at least in the brain of the rat. A series of studies will be performed to compare this new peptide with the well known anti-opioid peptide CCK-8, for which we have spent more than a decade to study its mechanisms of action. It is expected that elucidation of the role played by OFQ in pain and analgesia will open new insight into understanding the mechanisms governing the control of pain and analgesia in normal life and in patients suffering from severe pain. The third aim is to study the genetic factors determining the efficacy of EA analgesia, especially, to answer the question why EA works for some patients (the responders) and not for others (non-responders). Newly developed molecular genetic techniques including the gene knockout mouse will be used, and ways to change non-responders of EA into responders will be evaluated. In summary, "closer to clinical acupuncture practice and deeper to genetic level" will continue to be the theme of this proposal, in order to meet the challenge of an increasing expectation of using alternative medicine in health care and medical sciences.

IC Name
NATIONAL INSTITUTE ON DRUG ABUSE
  • Activity
    R01
  • Administering IC
    DA
  • Application Type
    2
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    999
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    NIDA
  • Study Section Name
    Neuropharmacology Research Subcommittee
  • Organization Name
    BEIJING MEDICAL UNIVERSITY
  • Organization Department
  • Organization DUNS
  • Organization City
    BEIJING
  • Organization State
  • Organization Country
    CHINA
  • Organization Zip Code
  • Organization District
    CHINA